GE Digs Deeper Into Biotech with New Irish Factories

September 19, 2016, 5:33 AM UTC
Immelt Stakes GE's Growth On Higher R&D As NBC, Finance Shrink
Fiona Ginty analyzes a cancerous tissue image from the Molecular Pathology Research Program at General Electric Co.'s (GE) Global Research Center in Niskayuna, New York, U.S., on Tuesday, July 13, 2010. This work is part of GE's collaboration with Eli Lilly & Co. to develop tissue-based diagnostics for predicting drug therapy responses. As Chairman Jeffrey Immelt prepares to sell NBC Universal and shrinks the company's GE Capital unit, he's betting GE's future growth on the ability to take new industrial offerings from development to market. GE divisions excluding media and finance provided 57 percent of the parent's $156.8 billion in sales last year. Photographer: Vijay Paruchuru/Bloomberg via Getty Images
Vijay Paruchuru/Bloomberg via Getty Images/File

General Electric (GE) is digging deeper into biotechnology with plans to build four prefabricated drug factories in Ireland, bringing to Europe a low-cost manufacturing concept it first pioneered in China.

The U.S. conglomerate, better known for making jet engines and turbines, said on Monday it would invest 150 million euros ($167 million) in a biopharmaceutical campus in county Cork. The new factories on the site will be owned and run by GE customers.

The GE BioPark Cork site is expected to create 500 jobs by the time it is fully operational, in a boost for Ireland, whose low tax rates have helped it attract top drug companies.

GE reckons its off-the-shelf modules are 25 to 50% cheaper than the traditional plants needed for making complex biological medicines. They can also be constructed in just 18 months rather than the typical three years.

See also: How Beth Comstock Is Lighting up GE

The first such GE prefab factory was built for JHL Biotech in China, where it recently started operations. Pfizer has also a so-called KUBio unit going up in China. Both these factories are designed to produce cut-price biosimilars, or copies of expensive biotech drugs.

Demand for such biosimilars is set to increase as patents expire on top-selling injectable medicines like AbbVie’s Humira for rheumatoid arthritis and Roche’s breast cancer treatment Herceptin.

KUBio factories offer GE a way to build up its presence in biotech medicine, which it sees as a central plank of its life sciences business. GE life sciences sales reached $4 billion in 2015, out of total GE Healthcare revenue of $18 billion.

Get Brainstorm Health Daily, Fortune’s newsletter on businesses betting big on advances in technology.

GE technology is already used to make leading antibody drugs and the company also aims to become a big supplier in the emerging field of cell therapy.

GE is expected to start building the factories in Cork next year. The investment is a boost for Ireland whose low tax regime has come under scrutiny. The Irish government is set to appeal against a 13-billion-euro back tax demand imposed by the European Commission on technology giant Apple, fearing it could undermine the country’s long-established policy of attracting multinationals with low taxes.

Ireland has been attracting drugmakers since the 1970s, helped more recently by its 12.5% corporate tax rate. Nine of the top 10 global drug companies today have an international base in Ireland.

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.